AR is lower in pKTx recipients on Tac vs CsA. Data comparing infection outcomes for children treated with these agents are limited. We retrospectively studied infection outcomes in 96 pKTx recipients on a RDP. PS, DCGS, AR, and infection-free survival were assessed using Kaplan-Meier/log-rank tests and proportional hazards models. There were no differences in 1-year PS, DCGS, or AR between Tac and CsA recipients. After adjusting for AR, the hazard of CMV viremia was 4.0 times higher (95%CI: 1.04, 15.5; P = .044) and that of BK viremia was 3.8 times higher (95%CI: 1.5, 10.2; P = .007) in Tac recipients. The incidence of EBV viremia was similar between the groups (P = .56).
| INTRODUCTION
The calcineurin inhibitors CsA and Tac were approved by the United States Food and Drug Administration in 1983 and 1997, respectively, for use in kidney transplantation to prevent AR. 1, 2 Clinical trials in kidney transplantation have shown improved kidney allograft survival with Tac compared to CsA when used as a part of maintenance immunosuppression protocols in both adult and pediatric KTx recipients. 3, 4 Increased rates of infectious complications have been observed with the use of more potent immunosuppression. 5, 6 Infections are now the leading cause of mortality and hospital readmissions in pediatric KTx recipients, 7 accounting for 24%-56% of deaths 8 and 24%
of PostTx hospitalizations. 9 We examined the relationship between calcineurin inhibitor use and infectious complications in pediatric KTx recipients on an RDP protocol at a single center. We did not find prior reports addressing this question in pediatric KTx recipients on steroid minimization protocols. As Tac may be more potent than CsA in terms 
O R I G I N A L A R T I C L E
Infection rates in tacrolimus versus cyclosporine-treated pediatric kidney transplant recipients on a rapid discontinuation of prednisone protocol: 1-year analysis planted after November 2011 to November 2014. For both CsA and Tac recipients, the calcineurin inhibitor was initiated on postoperative day 1-2 and dosed to achieve target levels as shown in Table 1 .
| Infection prophylaxis and diagnosis
Oral trimethoprim-sulfamethoxazole was given daily to all recipients as prophylaxis against UTI and Pneumocystis jiroveci infections. 12 Trimethoprim-sulfamethoxazole was started on day 
| Rejection
Recipients with a ≥25% increase in serum creatinine above baseline underwent a diagnostic kidney biopsy. All biopsies were read by a renal pathologist. Rejection was characterized as acute or chronic, tubulointerstitial, and/or vascular by established Banff criteria. 14 Acute cellular rejection episodes were treated with steroids only if mild and with Thymo if severe or steroid resistant. Antibody-mediated rejection episodes were treated with a combination of plasmapheresis and IVIG that were given every other day over a 10-day period.
| Outcomes and variables
Data collected on pediatric KTx patients included age at transplantation, gender, race, ethnicity, whether this was the primary transplant, 
| Statistical analysis
Patient demographic variables were summarized and compared be- All time to an event was calculated from date of transplant.
Rejections and infections were censored at date of graft failure or death. All analysis results were interpreted as statistically significant at the 0.05 level, and all analyses were performed using SAS 9.4 (The SAS Institute, Cary, NC, USA).
| RESULTS
Our study included 58 KTx recipients who received CsA and 38 who received Tac as part of the RDP maintenance immunosuppression protocol. The demographic and baseline transplant characteristics of the study participants are given in Table 2 . There was no significant difference between Tac and CsA recipients in terms of age at transplant, gender, race, prior transplant, PreTx dialysis, donor characteristics, or PreTx viral serology. The distribution of donor/recipient serology pairing for CMV (P = .60) and EBV (P = .67) was also similar between Tac and CsA recipients (Tables 3 and 4) . died suffered a sudden death of an unknown cause. The 1-year DCGS was similar between the two groups (95% vs 97%, P = .65). One patient lost his/her graft to thrombosis, one to chronic rejection, and two patients lost their grafts to recurrent disease. We did not find any difference in the acute rejection-free survival between Tac and CsA recipients (75% vs 77%, P = .89).
| Patient and graft survival

| Infection outcomes and PTLD
The incidence of CMV viremia was four times higher in Tac We did not find any difference in EBV viremia between Tac and CsA groups (21% vs 17%, P = 0.56) (Figure 3) . Of the 18 patients who developed EBV viremia during the first year PostTx, 11 (61%) were on valganciclovir prophylaxis at the time of the diagnosis. Similarly, there was no difference in the incidence of UTI (32% vs 31%, P = .84), pneumonia (11% vs 9%, P = .73), or Clostridium difficile infections (3% vs 7%, P = .39) between the two groups. PTLD was observed in one Tac recipient. We did not document any incidence of PTLD in CsA recipients.
| DISCUSSION
This is the first pediatric study to compare the rates of infectious complications after kidney transplantation in Tac and CsA recipients CMV is an important pathogen in pediatric and adult KTx recipients with an incidence of 8%-32%. 16, 17 Several risk factors for CMV infection have been identified in KTx recipients of which the most important are D+/R− status and the net state of immunosuppression.
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The latter is determined by the intensity of immunosuppression, coinfection with immunomodulating viruses, as well as rejection episodes requiring an escalation of immunosuppressive therapy. In our study, the two groups followed identical protocols for antiviral chemoprophylaxis. Tac recipients exhibited higher hazards of CMV viremia compared to CsA despite controlling for AR. Nafar et al. in their retrospective study of 427 KTx recipients also found Tac to be an independent risk factor for CMV infection compared to CsA. While most of our patients developed EBV viremia on prophylaxis, only one patient developed PTLD. Whether prophylaxis prevented PTLD in our cohort or not and how many patients would have developed EBV viremia without prophylaxis cannot be determined from our data.
Both asymptomatic CMV viremia and CMV disease have been shown in adult KTx recipients to increase the risk of graft loss and overall mortality beyond 100 days PostTx. 21 In our study, the overall rates of death and graft loss were low and there was no difference in the 1-year graft or patient survival between patients who did or did not develop CMV viremia within the first PostTx year. This difference in results may have been due to our small sample size.
We found a fourfold higher incidence of BK viremia in Tac In adults, the use of Tac in combination with MMF has been reported to result in higher mycophenolic acid levels compared to co-administration with CsA. [25] [26] [27] Similar findings were reported in a small pediatric study of liver transplant recipients. 28 Equivalent dosing of MMF in Tac and CsA recipients in our study may have resulted in higher net immunosuppression among Tac recipients. Mycophenolic acid levels and area under the curve (MPA-AUC) were not measured in the study population; hence, the exposure of the two groups to MMF could not be determined. As MPA is associated with higher rates of CMV viremia, 29 the higher CMV and BK rates in the Tac recipients may have been a consequence of excessive exposure to MPA. Based on our findings, we recommend that monitoring of MPA levels be considered in KTx recipients on Tac.
We observed only one case of PTLD in our study cohort and that was in a Tac recipient. Dharnidharka's study, unlike ours, patients were on a steroid inclusive maintenance immunosuppression protocol and some patients received induction with monoclonal anti-CD3 antibody (OKT3).
UTI, Clostridium difficile colitis, and respiratory infections have been described as common infectious complications in pediatric KTx recipients. [31] [32] [33] Our study did not demonstrate any significant difference in the incidence of these infections within the first PostTx year between the two groups.
F I G U R E 3 EBV-free survival according to maintenance immunosuppression in pKTx recipients
